- Home
- RBOT vs AVTX Comparison
RBOT vs AVTX Comparison
Compare RBOT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RBOT | AVTX |
|---|---|---|
| Price | $2.69 | $18.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $30.14 |
| AVG Volume (30 Days) | 150.4K | ★ 349.3K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.44 | $3.39 |
| 52 Week High | $18.97 | $20.72 |
Technical Indicators
Market Signals| Indicator | RBOT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 55.12 |
| Support Level | $2.70 | $15.53 |
| Resistance Level | $3.07 | $20.72 |
| Average True Range (ATR) | 0.34 | 1.47 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 6.94 | 59.44 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).